Suicide Risk Assessment in Ketamine-Assisted Therapy: A Clinical Guide
A clinical guide to suicide risk assessment in ketamine-assisted therapy—covering the C-SSRS, key risk and protective factors, safety planning protocols, documentation standards, and clinical decision-making.
Feb 26
/
Peter H Addy
Ketamine has demonstrated remarkable efficacy for treatment-resistant depression, PTSD, and chronic pain — conditions that frequently co-occur with elevated suicide risk. This overlap is not incidental. It's among the most important clinical realities that every ketamine-assisted therapy provider must be equipped to navigate.
Suicide risk assessment in ketamine-assisted therapy (KAP) is not a separate skill set grafted onto an existing clinical practice. It's a core competency that shapes every phase of the KAP process — from initial screening through discharge planning and follow-up care.
Why Suicide Risk Assessment Demands Particular Attention in KAP
The conditions most commonly treated with ketamine carry disproportionately elevated suicide risk. Treatment-resistant depression, PTSD, chronic pain with significant functional impairment, and substance use disorders all involve hopelessness, burdensomeness, and what can feel like inescapable suffering — the psychological conditions that most reliably elevate risk.
As I've noted in clinical supervision contexts: when someone is coming into your therapy office or your clinic for any condition that carries a higher likelihood of hopelessness, burdensomeness, and pain — whether that's physical or emotional — that's where we need to be more diligent in our risk assessment, not less. The motivation for seeking ketamine therapy is often itself a signal that deserves careful clinical attention.
Additionally, the altered states produced by ketamine require specific clinical thought: What does consent mean in an altered state? What monitoring is appropriate during a session? How does the post-session period — including the coming-down window — interact with risk?
The Key Components of a Thorough Suicide Risk Assessment
History of Previous Attempts
Previous suicide attempts remain the strongest single predictor of future attempts in the research literature. A thorough KAP intake must include detailed inquiry about past attempts — including method, lethality, intent, and the circumstances preceding each attempt. This history informs both treatment eligibility and the safety planning process.
Access to Means
Inquiring about access to lethal means — particularly firearms and stockpiled medications — is a standard clinical requirement that becomes more pressing in a population where the treatment itself involves medication that can be misused or stockpiled. Means restriction counseling, when appropriate, should be part of the safety planning process.
Risk Factors: A Dimensional Assessment
Categorical checklists of risk factors provide a starting point, but the clinical task is dimensional assessment — understanding how risk factors interact in this particular patient at this particular time. Core domains include:
- Psychiatric diagnoses: Depression, PTSD, and substance use disorders carry elevated base rates of suicide risk
- Hopelessness: Often a stronger predictor than depression severity alone
- Insomnia and sleep disruption: Consistently associated with elevated acute risk
- Chronic health conditions: Including chronic pain, which carries its own independent risk elevation
- Social isolation and recent losses
The Columbia Suicide Severity Rating Scale (C-SSRS) provides a standardized, validated framework for organizing this assessment and documenting it in a way that supports continuity of care. Using a standardized tool is not a replacement for clinical judgment — it supports it.
Protective Factors
Risk assessment that attends only to risk factors misses a clinically essential dimension. Protective factors moderate risk and inform treatment planning:
- Social support: Quality and availability of relationships the patient can draw on
- Future orientation: Plans, responsibilities, and commitments that function as reasons for living
- Dependents: Children, pets, and others the patient feels responsibility toward
- Religious or spiritual commitments
- Fear of death or the dying process
Identifying and explicitly strengthening protective factors — particularly social support and future orientation — is part of effective safety planning, not just assessment.
Implementing Assessment in KAP Practice
Create the Conditions for Honest Disclosure
Patients will not disclose suicidal ideation they fear will result in automatic hospitalization or loss of access to treatment. Creating a non-coercive, non-judgmental assessment environment — and being transparent about how you'll use the information you gather — is a prerequisite for accurate assessment. This is both ethical and clinically practical.
Use Standardized Tools Consistently
The C-SSRS, administered consistently at intake and at key transition points in treatment (before each ketamine session, in the post-session period, and at follow-up), provides documentation of your clinical reasoning and creates a baseline against which change can be measured. Thorough documentation of risk factors, protective factors, and your clinical judgment — including the rationale for any changes to the safety plan — is essential.
Collaborative Safety Planning
Safety planning in KAP is a collaborative process, not a document to be signed. It should include:
- Personalized coping strategies the patient can deploy early in a crisis
- Clear identification of warning signs that the patient and support network can recognize
- Emergency contacts, including crisis lines and the prescribing provider
- Means restriction agreements where appropriate
- Clear guidance on when and how to seek emergency care
Revisit the safety plan before each ketamine session and update it based on the patient's current state.
Coordinate Across the Care Team
KAP is a collaborative model. Suicide risk assessment findings and safety plans should be shared — with appropriate consent — with the prescribing medical provider and any other members of the patient's care team. Isolated clinical decision-making in this area represents a liability, both clinically and professionally.
Suicide risk assessment is not a task to complete and move past. It's an ongoing clinical practice that runs through every phase of ketamine-assisted therapy — from the first conversation through post-treatment follow-up. Developing genuine competence in this area is among the most important investments a KAP provider can make. For clinicians who want the full suite of assessment tools, the Comprehensive KAP Assessment Bundle covers medical screening, psychological assessment, and suicide risk assessment together.
The more you practice this assessment, the more reliably you'll develop the clinical intuition that supports it: a sense of who is in acute distress, what factors are driving that distress, and how to intervene in ways that genuinely improve safety rather than simply documenting it. As I tell clinicians I supervise: it's a matter of practice. The more you know and the more you try, the easier it becomes.
